Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03823625
Title An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione Ricerca Traslazionale
Indications

lung squamous cell carcinoma

Therapies

Ipilimumab + Nivolumab

Carboplatin + Gemcitabine + Nivolumab

Carboplatin + Nivolumab + Paclitaxel

Cisplatin + Gemcitabine + Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.